Corvus Pharmaceuticals (CRVS) Return on Capital Employed (2016 - 2026)
Corvus Pharmaceuticals' (CRVS) quarterly Return on Capital Employed came in at 30.41% in Q1 2026, up 2308.0% year-on-year from 1.26% in Q1 2025, and up 38.48% quarter-over-quarter from 49.43% in Q3 2025.
Corvus Pharmaceuticals (CRVS) Return on Capital Employed (2016 - 2026) Analysis & Trends
Corvus Pharmaceuticals' Return on Capital Employed history runs 11 years deep, the most recent figure standing at 30.41% for Q1 2026.
- On a quarterly basis, Return on Capital Employed rose 2308.0% year-over-year to 30.41% in Q1 2026; TTM through Mar 2026 was 30.41%, a 2308.0% increase from a year earlier, with the FY2023 full-year figure at 46.79%, down 509.0% from the prior year.
- Return on Capital Employed rose to 30.41% in Q1 2026 per CRVS's latest filing, from 49.43% in the prior quarter.
- Across five years, Return on Capital Employed topped out at 30.41% in Q1 2026 and bottomed at 164.21% in Q3 2024.
- The 5-year median for Return on Capital Employed is 51.25% (2022), against an average of 57.59%.
- Across the five-year window, Return on Capital Employed tumbled 11510 bps in 2024 and soared 11478 bps in 2025, its largest moves.
- Year by year, Return on Capital Employed stood at 51.25% in 2022, then decreased by 9 bps to 55.89% in 2023, then tumbled by 194 bps to 164.21% in 2024, then jumped by 70 bps to 49.43% in 2025, then jumped by 38 bps to 30.41% in 2026.
- Per Business Quant, the three latest CRVS Return on Capital Employed figures stand at 30.41% (Q1 2026), 49.43% (Q3 2025), and 50.61% (Q2 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -31.80% |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 10.46% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -68.47% |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 21.10% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 10.19% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -68.84% |
| 10 | Corvus Pharmaceuticals | 1.23 Bn | 1.23 Bn | - | -30.41% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -30.41% |
| Sep 30, 2025 | -49.43% |
| Jun 30, 2025 | -50.61% |
| Mar 31, 2025 | -53.49% |
| Sep 30, 2024 | -164.21% |
| Jun 30, 2024 | -60.02% |
| Mar 31, 2024 | -63.95% |
| Dec 31, 2023 | -55.89% |
| Sep 30, 2023 | -49.11% |
| Jun 30, 2023 | -60.35% |
| Mar 31, 2023 | -57.76% |
| Dec 31, 2022 | -51.25% |
| Sep 30, 2022 | -46.52% |
| Jun 30, 2022 | -34.90% |
| Mar 31, 2022 | -35.96% |
| Dec 31, 2021 | -36.90% |
| Sep 30, 2021 | -40.46% |
| Jun 30, 2021 | -43.83% |
| Mar 31, 2021 | -50.29% |
| Dec 31, 2020 | -74.74% |